Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis

Ophthalmology

Volumn 111, Issue 2, 2004, Pages 352-356

  Murphy, Conor C ^a   Ayliffe, William H ^b   Booth, Anthony ^c   Makanjuola, David ^c   Andrews, Peter A ^c   Jayne, David ^c  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORNEA; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EYE INFECTION; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REDUCTION; REFRACTORY UVEITIS; REMISSION; RETROSPECTIVE STUDY; SCLERITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UVEITIS; VISUAL ACUITY;

EID: 0842331999     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00721-8     Document Type: Article

References (22)

1. Suttorp-Schulten M.S., Rothova A. The possible impact of uveitis in blindness a literature survey . Br J Ophthalmol. 80:1996;844-848.
2. Jabs D.A., Mudun A., Dunn J.P., Marsh M.J. Episcleritis and scleritis clinical features and treatment results . Am J Ophthalmol. 130:2000;469-476.
3. Weiner A., BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol. 112:(2):1991;151-158.
4. Rothova A., Buitenhuis H.J., Meenken C., et al. Uveitis and systemic disease. Br J Ophthalmol. 76:(3):1992;137-141.
5. Forrester J.V. Duke-Elder Lecture new concepts on the role of autoimmunity in the pathogenesis of uveitis . Eye. 6:1992;433-446.
6. Elliott M.J., Maini R.N., Feldmann M., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
7. Lipsky P.E., van der Heijde D.M.F., St Claire E.W., et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 343:2000;1594-1602.
8. Targan S.R., Hanauer S.B., van Deventer S.J., et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 337:1997;1029-1035.
9. Kijlstra A. Cytokines their role in uveal disease . Eye. 11:1997;200-205.
10. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 358:2001;295-296.
11. Ogilvie A.L., Antoni C., Dechant C., et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 144:2001;587-589.
12. Booth A., Jefferson H.J., Ayliffe W., et al. Safety and efficacy of TNF alpha blockade in relapsing vasculitis [letter]. Ann Rheum Dis. 61:2002;559.
13. Forrester J.V. Uveitis pathogenesis . Lancet. 388:1991;1498-1501.
14. de Vos A.F., Hoekzema R., Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res. 11:1992;581-597.
15. Beutler B., Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Ann Rev Immunol. 7:1989;625-655.
16. Franks W.A., Limb G.A., Stanford M.R., et al. Cytokines in human intraocular inflammation. Curr Eye Res. 11:(suppl):1992;187-191.
17. Dick A.D., Duncan L., Hale G., et al. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. 11:1998;255-264.
18. Brito B.E., O'Rourke L.M., Pan Y., et al. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci. 40:1999;2583-2589.
19. Muñoz-Fernández S., Hidalgo V., Fernández- Melón J., et al. Effect of infliximab on threatening panuveitis in Behçet's disease [letter]. Lancet. 358:2001;1644.
20. Fries W., Giofre M.R., Catonoso M., Lo Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab [letter]. Am J Gastroenterol. 97:2002;499-500.
21. Smith J.R., Levinson R.D., Holland G.N., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 45:2001;252-257.
22. Hanauer S.B. Review article safety of infliximab in clinical trials . Aliment Pharmacol Ther. 13:(suppl 4):1999;16-22.